We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Test Determines Genetic Resistance to HIV

By HospiMedica staff writers
Posted on 07 Jul 2006
A test has been developed that determines if a person is a fast, neutral, or slow progressor to AIDS after human immunodeficiency virus (HIV) infection. More...


The results of the test help individuals infected with HIV know how quickly the virus is likely to cause disease, enabling physicians to decide how aggressive the therapy needs to be for each patient.

The test was developed by Independent Forensics (Jersey City, NJ, USA). It measures the genetics of CCR5 receptors on T-cells and uses a simple buccal swab collection procedure, which can be easily carried out at home. Test results are available in three weeks. CCR5 is the primary HIV receptor in T-cells, and people contain varying amounts of this receptor according to their genetic make-up. The fewer available CCR5 receptors people have, the more likely it is that they will demonstrate a slow progression to AIDS when infected with HIV-1.

"We believe the CCR5 halotype test is one of the most important things an individual with HIV can do to help in their treatment. It is part of our philosophy to 'Know Thyself', knowing your own genetic makeup will help everyone make informed and healthy life decisions,” explained Jack Keehma, CEO of Independent Forensics.

Independent Forensics' services include paternity, immigration, Codis data basing, casework, expert witness testimony, and product development for the forensic community. The company's products include SampleTrak software and rapid-stain identification tests for saliva and semen.



Related Links:
Independent Forensics

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.